Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer-Reference-Cited by-同舟云学术

Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

Published:2014-01-06 Issue:3 Volume:5 Page:667-678
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Al Nakouzi Nader¹²³,Cotteret Sophie¹²³,Commo Frédéric²³,Gaudin Catherine¹²³,Rajpar Shanna¹²³,Dessen Philippe⁴³,Vielh Philippe²⁵³,Fizazi Karim¹²⁶³,Chauchereau Anne¹²³

Affiliation:

1. Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France

2. INSERM U981, LabEx LERMIT, Gustave Roussy

3. University Paris-Sud 11, France

4. INSERM U985, Gustave Roussy

5. Department of Pathology, HistoCytoPathology Unit, Translational Research Laboratory and Biobank, Gustave Roussy

6. Department of Medicine, Gustave Roussy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A vitamin D‐based strategy overcomes chemoresistance in prostate cancer;British Journal of Pharmacology;2024-07-09

2. Identification of Candidate Diagnostic gene CDC25C for Trametinib-induced Cardiotoxicity by Integrating Bioinformatics and Machine Learning;2024-05-08

3. Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri‐microRNA‐129 maturation;Environmental Toxicology;2024-03-28

4. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development;World Journal of Gastrointestinal Oncology;2023-10-15

5. Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer;iScience;2023-09